Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07165067Phase 1Recruiting

A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors

Role: lead

NCT06669975Phase 1Recruiting

A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

Role: lead

NCT05473156Phase 1Recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Role: lead

NCT06723964Phase 1Active Not Recruiting

A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

Role: lead

All 4 trials loaded